GREENWICH LIFESCIENCES

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company, pioneering an immunotherapy vaccine called GLSI-100, which is designed to activate the immune system in preventing breast cancer recurrences in HER2-positive patients... Business Description: Greenwich LifeSciences (the "Company") is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or "over-expressor") levels.

Also known as: Greenwich LifeSciences, Inc.

Primary location: Stafford United States